SIGNIFY HEALTH INC -CLASS A (SGFY) Stock Analyst Ratings
USA - NYSE:SGFY - US82671G1004 - Common Stock
30.49 USD
+0.02 (+0.07%)
30.49 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 70% to SGFY. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 30.01. This target is -1.59% below the current price.
SGFY was analyzed by 16 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about SGFY.
In the previous month the buy percentage consensus was at a similar level.
SGFY was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-09-07 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-09-07 | BTIG | Downgrade | Buy -> Neutral |
| 2022-09-07 | UBS | Downgrade | Buy -> Neutral |
| 2022-09-07 | Truist Securities | Initiate | Hold |
| 2022-09-06 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-09-06 | RBC Capital | Maintains | Sector Perform |
| 2022-09-06 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2022-09-06 | Baird | Downgrade | Outperform -> Neutral |
| 2022-09-06 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-08-31 | BTIG | Initiate | Buy |
| 2022-08-17 | Guggenheim | Maintains | Buy |
| 2022-08-17 | Deutsche Bank | Maintains | Buy |
| 2022-07-29 | RBC Capital | Initiate | Sector Perform |
| 2022-06-06 | Piper Sandler | Maintains | Overweight |
| 2022-05-16 | Baird | Upgrade | Neutral -> Outperform |
| 2022-03-09 | UBS | Upgrade | Neutral -> Buy |
| 2022-03-09 | Cowen & Co. | Maintains | Market Perform |
| 2022-03-07 | Piper Sandler | Maintains | Overweight |
| 2022-02-11 | Goldman Sachs | Initiate | Buy |
| 2021-09-23 | Baird | Downgrade | Outperform -> Neutral |
| 2021-09-10 | Cowen & Co. | Initiate | Market Perform |
| 2021-08-12 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-05-28 | Baird | Initiate | Outperform |
| 2021-03-08 | William Blair | Initiate | Outperform |
| 2021-03-08 | UBS | Initiate | Neutral |
| 2021-03-08 | Deutsche Bank | Initiate | Buy |
| 2021-03-08 | Barclays | Initiate | Equal-Weight |
| 2021-03-08 | Goldman Sachs | Initiate | Neutral |
| 2021-03-08 | B of A Securities | Initiate | Buy |
SIGNIFY HEALTH INC -CLASS A / SGFY FAQ
What do analysts expect the price target to be for SIGNIFY HEALTH INC -CLASS A (SGFY)?
16 analysts have analysed SGFY and the average price target is 30.01 USD. This implies a price decrease of -1.59% is expected in the next year compared to the current price of 30.49.
What is the consensus rating for SGFY stock?
The consensus rating for SIGNIFY HEALTH INC -CLASS A (SGFY) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for SIGNIFY HEALTH INC -CLASS A stock?
The number of analysts covering SIGNIFY HEALTH INC -CLASS A (SGFY) is 16.